We are live on ! Find out more
PRTK

Paratek Pharmaceuticals, Inc.
PRTK

Delisted

PRTK was delisted on the 20th of September, 2023.

Back to rankings

119 hedge funds and large institutions have $564M invested in Paratek Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 48 increasing their positions, 26 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more call options, than puts

Call options by funds: $7.58M | Put options by funds: $3.35M

113% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 15

85% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 26

45% more capital invested

Capital invested by funds: $389M → $564M (+$174M)

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

16% more funds holding

Funds holding: 103 → 119 (+16)

Holders
119
Holders Change
+16
Holders Change %
+15.53%
% of All Funds
2.97%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.15%
New
32
Increased
48
Reduced
26
Closed
15
Calls
$7.58M
Puts
$3.35M
Net Calls
+$4.24M
Net Calls Change
+$29.6M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$8.59M
2
CWG
C WorldWide Group
Denmark
+$7.95M
3
BG
Baupost Group
Massachusetts
+$7.74M
4
PAMU
Pictet Asset Management (UK)
United Kingdom
+$7.67M
5
Invesco
Invesco
Georgia
+$7.61M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$14.5M
2
Millennium Management
Millennium Management
New York
-$10.8M
3
GPP
Great Point Partners
Connecticut
-$10.4M
4
TCM
Tekla Capital Management
Massachusetts
-$5.08M
5
DAM
DLD Asset Management
New York
-$4.78M
Name Holding Trade Value Shares
Change 		Change in
Stake
NI
26
Numeric Investors
Massachusetts
$6.45M +$5.92M +267,600 New
Adage Capital Partners
27
Adage Capital Partners
Massachusetts
$6.36M +$4.92M +222,461 +537%
RAM
28
Roumell Asset Management
Maryland
$6.21M +$304K +13,765 +6%
CS
29
Candriam SCA
Luxembourg
$5.47M +$2.37M +107,000 +89%
NIP
30
Nicholas Investment Partners
California
$4.92M +$3.84M +173,717 +573%
JP Morgan Chase
31
JP Morgan Chase
New York
$4.81M +$4.19M +189,730 +1,898%
Geode Capital Management
32
Geode Capital Management
Massachusetts
$4.57M +$895K +40,485 +27%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$4.16M +$1.96M +88,454 +105%
Alyeska Investment Group
34
Alyeska Investment Group
Illinois
$3.85M +$3.53M +159,814 New
SSA
35
Schonfeld Strategic Advisors
New York
$3.5M +$1.66M +75,017 +107%
EI
36
EAM Investors
California
$3.47M +$3.18M +144,022 New
Morgan Stanley
37
Morgan Stanley
New York
$3.4M -$304K -13,770 -9%
DCM
38
Driehaus Capital Management
Illinois
$3.31M +$3.03M +137,228 New
Boston Partners
39
Boston Partners
Massachusetts
$3.22M -$512K -23,176 -15%
Goldman Sachs
40
Goldman Sachs
New York
$3.17M +$1.95M +88,222 +203%
TCIM
41
TIAA CREF Investment Management
New York
$2.24M +$397K +17,971 +24%
RIM
42
Rainier Investment Management
Washington
$2.07M +$146K +6,620 +8%
PPA
43
Parametric Portfolio Associates
Washington
$1.75M +$1.6M +72,493 New
CM
44
Crestline Management
Texas
$1.73M +$1.59M +71,799 New
NMC
45
NEA Management Company
Maryland
$1.6M – – –
AI
46
Axiom Investors
Connecticut
$1.54M +$1.41M +63,882 New
Russell Investments Group
47
Russell Investments Group
United Kingdom
$1.54M +$1.17M +52,818 +482%
Allianz Asset Management
48
Allianz Asset Management
Germany
$1.49M +$301K +13,628 +28%
UBS Group
49
UBS Group
Switzerland
$1.48M +$1.36M +61,526 New
IBT
50
International Biotechnology Trust
United Kingdom
$1.4M +$1.28M +58,000 New
1
2
3 4 5

PRTK Hedge Fund Activity: Q2 2017 in Review

119 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q2 2017, worth a combined $564M — up 45% from $389M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new PRTK positions and 15 closed out — a net gain of 17 holders — while 48 added to existing stakes and 26 trimmed.

The largest buyer was BlackRock, adding an estimated $8.59M. The largest seller was Fidelity Investments, cutting an estimated $14.5M.

  • 119 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q2 2017, up from 103 in Q1 2017.
  • Funds reported $564M of Paratek Pharmaceuticals, Inc. stock for Q2 2017, up 45% quarter-over-quarter.
  • 32 funds opened new Paratek Pharmaceuticals, Inc. positions in Q2 2017 and 15 closed out, a net change of +17 holders.
  • The largest Paratek Pharmaceuticals, Inc. buyer in Q2 2017 was BlackRock, an estimated $8.59M added.
  • The largest Paratek Pharmaceuticals, Inc. seller in Q2 2017 was Fidelity Investments, an estimated $14.5M sold.

Based on aggregated 13F filings for Q2 2017.